| Objective: To evaluate the risk of all-cause mortality and cardiovascular events in patients with type 2 diabetes mellitus treated with glimepiride and glibenclamide to guide the selection of clinically sulfonylureas.Methods: "Death" or "death" or "cardiovascular system" or "cardiovascular disease" or "coronary heart disease" or "acute coronary syndrome" or "Myocardial infarction " or " heart failure " or " arrhythmia " or " stroke " in the Chinese database(Wanfang,Chongqing Vipu,Tsinghua Tongfang,etc.)for keyword search and free word search;to " Glimepiride " or " glibenclamide " and "Mortality" or "death" or "cardiovascular system" or "cardiovascular disease" or "coronary heart disease" or "acute coronary syndrome" or "myocardium Infarct" or "heart failure" or "arrhythmia" or "stroke" Database(cochrane,medline,embase,etc.)for keyword search and free word search.The year of publication of the literature is not limited,including English and Chinese.Screen out the selected literatures through the inclusion criteria and the exclusion criteria,then evaluate the quality of the selected literature.Two independent systemevaluators extract and check the data,and then use STATA11.0 With Meta software for statistical analysis.Results: A total of 16 articles were included,one of which was a randomized controlled trial ,one for the case-control study ,and 14 for the cohort study.Meta analysis showed that the all-cause mortality of glimepiride and glibenclamide [P=0.845,HR=1.005,95%CI(0.956,1.056)],suggesting that there was no statistically significant difference between the two groups.The risk of cardiovascular events in glimepiride and glibenclamide[P=0.059,HR=0.881,95%CI(0.772,1.005)],suggests that the difference between the two is not statistically significant.Conclusion: Glimepiride,in contrast to glibenclamide,failed to reduce the risk of all-cause mortality and the risk of cardiovascular events. |
PDF Full Text Request